Weiner; David M.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Weiner; David M..The latest application filed is for "selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases".

Company Profile

4.19.31

Weiner; David M. - San Diego CA
- San Diego CA US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Selective Serotonin 2a/2c Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases App 20220241265 - Weiner; David M. ; et al.	2022-08-04
Selective Serotonin 2a/2c Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases App 20200323836 - Weiner; David M. ; et al.	2020-10-15
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 10,525,046 - Weiner , et al. J	2020-01-07
Selective Serotonin 2a/2c Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases App 20190030015 - Weiner; David M. ; et al.	2019-01-31
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 10,028,944 - Weiner , et al. July 24, 2	2018-07-24
Selective Serotonin 2a/2c Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases App 20170209424 - Weiner; David M. ; et al.	2017-07-27
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 9,566,271 - Weiner , et al. February 14, 2	2017-02-14
Selective Serotonin 2a/2c Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases App 20160250200 - Weiner; David M. ; et al.	2016-09-01
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 9,211,289 - Weiner , et al. December 15, 2	2015-12-15
Selective Serotonin 2a/2c Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases App 20150202194 - Weiner; David M. ; et al.	2015-07-23
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 8,921,393 - Weiner , et al. December 30, 2	2014-12-30
Selective Serotonin 2a/2c Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases App 20140140982 - Weiner; David M. ; et al.	2014-05-22
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 8,618,130 - Weiner , et al. December 31, 2	2013-12-31
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 08618130 -	2013-12-31
Selective Serotonin 2a/2c Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases App 20130137727 - WEINER; David M. ; et al.	2013-05-30
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 8,377,959 - Weiner , et al. February 19, 2	2013-02-19
Selective Serotonin 2a/2c Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases App 20120277221 - WEINER; David M. ; et al.	2012-11-01
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 8,227,487 - Weiner , et al. July 24, 2	2012-07-24
Selective Serotonin 2a/2c Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases App 20110257229 - WEINER; David M. ; et al.	2011-10-20
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 8,008,323 - Weiner , et al. August 30, 2	2011-08-30
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 7,994,193 - Weiner , et al. August 9, 2	2011-08-09
Selective serotonin receptor inverse agonists as therapeutics for disease Grant 7,875,632 - Weiner , et al. January 25, 2	2011-01-25
Selective serotonin receptor inverse agonists as therapeutics for disease Grant 7,863,296 - Weiner , et al. January 4, 2	2011-01-04
Selective serotonin receptor inverse agonists as therapeutics for disease Grant 7,820,695 - Weiner , et al. October 26, 2	2010-10-26
Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases App 20100227886 - WEINER; David M. ; et al.	2010-09-09
Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases App 20100227885 - WEINER; David M. ; et al.	2010-09-09
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 7,732,462 - Weiner , et al. June 8, 2	2010-06-08
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 7,713,995 - Weiner , et al. May 11, 2	2010-05-11
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 7,659,285 - Weiner , et al. February 9, 2	2010-02-09
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Grant 7,601,740 - Weiner , et al. October 13, 2	2009-10-13
Selective serotonin receptor inverse agonists as therapeutics for disease App 20090155389 - Weiner; David M. ; et al.	2009-06-18
Use Of N-desmethylclozapine To Treat Human Neuropsychiatric Disease App 20090018119 - Weiner; David M. ; et al.	2009-01-15
G-protein Coupled Receptors High-throughput Functional Assay App 20080280303 - Burstein; Ethan S. ; et al.	2008-11-13
Clinical indications for genotyping polymorphic variants of G-protein coupled receptors Grant 7,348,140 - Weiner , et al. March 25, 2	2008-03-25
Use Of 4-amino-piperidines For Treating Sleep Disorders App 20080051429 - van Kammen; Daniel ; et al.	2008-02-28
Use Of N-desmethylclozapine To Treat Human Neuropsychiatric Disease App 20070275957 - Weiner; David M. ; et al.	2007-11-29
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases App 20060264465 - Weiner; David M. ; et al.	2006-11-23
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases App 20060264466 - Weiner; David M. ; et al.	2006-11-23
Use of N-desmethylclozapine to treat human neuropsychia tric disease App 20060199807 - Weiner; David M. ; et al.	2006-09-07
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases App 20060199842 - Weiner; David M. ; et al.	2006-09-07
Use of N-desmethylclozapine to treat human neuropsychiatric disease App 20060194831 - Weiner; David M. ; et al.	2006-08-31
Selective serotonin receptor inverse agonists as therapeutics for disease App 20050288328 - Weiner, David M. ; et al.	2005-12-29
Selective serotonin receptor inverse agonists as therapeutics for disease App 20050261340 - Weiner, David M. ; et al.	2005-11-24
Selective serotonin receptor inverse agonists as therapeutics for disease App 20050261278 - Weiner, David M. ; et al.	2005-11-24
Use of N-desmethylclozapine to treat human neuropsychiatric disease App 20050250767 - Weiner, David M. ; et al.	2005-11-10
G-protein coupled receptors high-throughput functional assay App 20050123964 - Burstein, Ethan S. ; et al.	2005-06-09
Use of N-desmethylclozapine to treat human neuropsychiatric disease App 20050085463 - Weiner, David M. ; et al.	2005-04-21
Use of N-desmethylclozapine to treat human neuropsychiatric disease App 20040224942 - Weiner, David M. ; et al.	2004-11-11
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases App 20040213816 - Weiner, David M. ; et al.	2004-10-28

Company Registrations

SEC

0001641211

Weiner David M.

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.